Enhances the company’s capabilities to accelerate next-generation therapies by optimizing antibody purification
MilliporeSigma, which is part of Merck KGaA based in Darmstadt, Germany, and operates in the U.S. and Canada as the Life Science division, has announced that Merck’s Life Science business has reached an agreement to buy the chromatography division of JSR Life Sciences. JSR is well known for its skills in developing and making products for biopharmaceuticals and offering bioprocessing solutions. This acquisition will help MilliporeSigma improve its downstream processing abilities by adding advanced Protein A chromatography solutions to its offerings. These solutions are key for making the production of biopharmaceuticals, especially monoclonal antibodies, more efficient and able to scale up. The deal is expected to finish by the end of the second quarter in 2026.
Health Technology Insights: Alpha Cognition Prices $35 Million Public Offering of Shares
This move shows MilliporeSigma’s plan to become stronger in the bioprocessing field and keep investing in technologies that help make monoclonal antibody therapies. Sebastián Arana, who leads Process Solutions for Merck KGaA’s Life Science business, said that combining JSR’s Protein A expertise with their current products will help customers make their antibody production processes faster, more reliable, and more efficient.
Health Technology Insights: BrightPath Cecil Expands Student Mental Health Support
Protein A chromatography is a crucial step in purifying monoclonal antibodies and other therapeutic proteins used to treat diseases like cancer, autoimmune conditions, and infections. This process is important for keeping the product clean and safe, while also making production quicker and more dependable. These improvements help patients get life-saving treatments sooner.
The chromatography division being bought is located in Belgium and has more than 50 employees. It helps pharmaceutical and biotech companies worldwide with purification solutions. The division is recognized for its Amsphere A3 and Amsphere A+ Protein A resins, which are known for their high performance and consistency in processes, especially when handling a variety of monoclonal antibodies.
Tim Lowery, President of JSR Life Sciences, said that this change will let their innovative Amsphere Protein A technologies reach a larger global market. He added that joining Merck KGaA’s network will help more customers bring treatments to patients quicker and with more confidence in their production processes. MilliporeSigma already offers a wide range of tools for downstream processing, including top-quality filtration systems, chromatography resins, buffer solutions, processing equipment, and validation services. The company aims to keep helping pharmaceutical manufacturers by making drug development and production faster, safer, and more reliable.
Health Technology Insights: Perficient Study Shows Rising Demand for Digital Healthcare Access
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
